Replies to post #6700 on ANI Pharmaceuticals (ANIP)

[jadite]

Keep in mind that Proctor and Gamble demonstrated efficacy that satisfied the FDA with their Intrinsa clinical trials. Intrinsa is basically Libigel on a band-aid.

The only reason Intrinsa was rejected was safety. That's why investors were thrown into a tailspin when Libigel was rejected!

https://www.thestreet.com/story/10200668/2/biosante-plans-fda-meeting-on-female-sexual-dysfunction-gel.html

[Just the facts maam]

Jeff, according to Biotech Due Diligence it appears that The July 2011 Leerink Swann analyst report was of the impression that Efficacy was being captured in the safety study. Unfortunately the original report is no longer available.

Leerink Swann

This is further supported by the American Heart Journal "A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder" in January 2012 listing Dr Snabes and Joanne Zborowski (Biosante) as authors.

AJH arrticle